FDA clears Phase 1 testing of NDC-011 dual combination ALS therapy
The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase…
Articles by Margarida Maia, PhD
Targeting 3 cell types at same time seen to extend survival in ALS mice
A strategy that simultaneously targets motor neurons, astrocytes, and microglia — three cell types involved in the development and progression…
Benefits of repurposed monepantel for ALS sustained for up to 2 years
Monepantel, a veterinary drug that PharmAust is repurposing for amyotrophic lateral sclerosis (ALS), continues to slow disease…
MDA seeks applications for advocacy collaboration grants
The Muscular Dystrophy Association (MDA) is accepting applications for its Advocacy Collaboration Grant program, which supports projects from organizations…
Pete Frates’ family launches Ice Bucket Challenge 2.0 for ALS
A decade later, the family of Pete Frates, the amyotrophic lateral sclerosis (ALS) patient who helped start the…
TPN-101 shows long-term benefits in C9orf72-related ALS in trial
Nearly a year of treatment with TPN-101, an investigational oral molecule from Transposon Therapeutics, safely slowed disease progression and…
Early PrimeC initiation slows lung function decline, trial data show
People with amyotrophic lateral sclerosis (ALS) who received one year of treatment with PrimeC, an experimental oral tablet from…
Blood NfL levels are impacted by ALS clinical subtype, study finds
Elevated blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, are linked to faster disease progression…
Europe’s CHMP recommends against masitinib authorization
An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as…
Fasudil safe, preserves motor neurons in early-stage ALS: Study
Treatment with fasudil (RT1968), which Raya Therapeutic is testing for amyotrophic lateral sclerosis (ALS), was safe and outperformed…